Faron Pharmaceuticals Oy Share Forecast, Price & News

GBX 360
+15.00 (+4.35 %)
(As of 04/16/2021 02:00 PM ET)
Today's Range
Now: GBX 360
50-Day Range
MA: GBX 333.80
52-Week Range
Now: GBX 360
Volume12,108 shs
Average Volume47,055 shs
Market Capitalization£181.50 million
P/E RatioN/A
Dividend YieldN/A
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Faron Pharmaceuticals Oy logo

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual Sales£2.12 million
Cash FlowGBX 9.32 per share
Book ValueGBX (3.90) per share



Market Cap£181.50 million
Next Earnings DateN/A
OptionableNot Optionable


Faron Pharmaceuticals Oy (LON:FARN) Stock Price Up 3.4%
March 30, 2021 |  americanbankingnews.com
Faron Pharma. Oy - Exercise of Options
March 26, 2021 |  proactiveinvestors.com
Results of Placing and Issue Price: Faron Pharmaceuticals Oy
February 12, 2021 |  finance.yahoo.com
Faron Pharmaceuticals Oyj
February 5, 2021 |  barrons.com
Faron Pharma. Oy - Second Price Monitoring Extn
January 20, 2021 |  proactiveinvestors.com.au
News for Faron Pharmaceuticals Oy
December 24, 2020 |  markets.businessinsider.com
John Poulos Appointed to Memgen's Board of Directors
November 19, 2020 |  finanznachrichten.de
August 20, 2020 |  au.finance.yahoo.com
Will Faron Pharmaceuticals Oy's price keep rising?
August 20, 2020 |  uk.finance.yahoo.com
Faron Pharmaceuticals Oy (FPHAF)
August 2, 2020 |  finance.yahoo.com
Faron Pharma Regulatory News
July 9, 2020 |  www.lse.co.uk
See More Headlines


Overall MarketRank

0.64 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 360
+15.00 (+4.35 %)
(As of 04/16/2021 02:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FARN News and Ratings via Email

Sign-up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Faron Pharmaceuticals Oy (LON:FARN) Frequently Asked Questions

What stocks does MarketBeat like better than Faron Pharmaceuticals Oy?

Wall Street analysts have given Faron Pharmaceuticals Oy a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Faron Pharmaceuticals Oy wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Faron Pharmaceuticals Oy's stock been impacted by Coronavirus?

Faron Pharmaceuticals Oy's stock was trading at GBX 297.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FARN shares have increased by 21.0% and is now trading at GBX 360.
View which stocks have been most impacted by COVID-19

Who are Faron Pharmaceuticals Oy's key executives?

Faron Pharmaceuticals Oy's management team includes the following people:
  • Dr. Juho Markku Jalkanen, Chief Devel. Officer (Age 43)
  • Dr. Markku Tapani Jalkanen, Founder, CEO & Exec. Director (Age 66)
  • Mr. Toni Hänninen, Chief Financial Officer
  • Dr. Mikael Maksimow Ph.D., VP of Operations (Age 45)
  • Dr. Matti Karvonen, Chief Medical Officer & VP of Drug Devel.
  • Dr. Juhana Heinonen, Chief Commercial Officer
  • Dr. Ilse Piippo, Regulatory Consultant (Age 72)

Who are some of Faron Pharmaceuticals Oy's key competitors?

What other stocks do shareholders of Faron Pharmaceuticals Oy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), (CELG), Acura Pharmaceuticals (ACUR), Carnival Co. & (CCL), Alphabet (GOOG), Hurricane Energy (HUR), International Consolidated Airlines Group (IAG), Northwest Pipe (NWPX), Petropavlovsk (POG) and 760792 (TQNT).

What is Faron Pharmaceuticals Oy's stock symbol?

Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN."

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Faron Pharmaceuticals Oy's stock price today?

One share of FARN stock can currently be purchased for approximately GBX 360.

How much money does Faron Pharmaceuticals Oy make?

Faron Pharmaceuticals Oy has a market capitalization of £181.50 million and generates £2.12 million in revenue each year.

How many employees does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy employs 24 workers across the globe.

What is Faron Pharmaceuticals Oy's official website?

The official website for Faron Pharmaceuticals Oy is www.faron.com.

Where are Faron Pharmaceuticals Oy's headquarters?

Faron Pharmaceuticals Oy is headquartered at Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland.

How can I contact Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151.

This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.